Lonza Group AG stock (CH0013841017): Ex-dividend date set for May 12

Lonza Group AG shareholders must buy shares by May 11 to qualify for the 5.138 USD dividend per share, payable May 15. The stock goes ex-dividend on May 12 on SIX Swiss Exchange and US OTC markets.

Lonza Group AG goes ex-dividend on May 12, 2026, with shareholders of record on May 13 eligible for a dividend of 5.138 USD per share, paid out on May 15, according to Deutsche Boerse as of May 11, 2026. This payout reflects the company's steady capital returns to investors. Separately, Morningstar upgraded its rating on Lonza Group AG to buy from hold on May 11, 2026, while retaining a price target of 550 CHF, per MarketScreener as of May 11, 2026.

As of: 11.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Lonza Group
• Sector/industry: Biopharmaceutical contract development and manufacturing (CDMO)
• Headquarters/country: Basel, Switzerland
• Core markets: US, Europe, Asia
• Key revenue drivers: Biologics manufacturing, cell & gene therapies
• Home exchange/listing venue: SIX Swiss Exchange (LONN), OTC US (LZAGF)
• Trading currency: CHF (primary), USD (OTC)

Lonza Group AG: core business model

Lonza Group AG is a leading contract development and manufacturing organization (CDMO) in the biopharmaceutical sector. It supports clients from early-stage development through commercial-scale production, focusing on biologics, small molecules, cell and gene therapies, and capsules and health ingredients, according to Morningstar as of May 11, 2026. The company operates under four main segments, serving global pharma firms with high switching costs and long-term contracts.

Headquartered in Basel, Switzerland, Lonza Group AG emphasizes innovation in complex manufacturing technologies, positioning it as a key partner for biotech and pharmaceutical companies worldwide.

Main revenue and product drivers for Lonza Group AG

Biologics manufacturing and cell & gene therapies represent core revenue drivers for Lonza Group AG, fueled by rising demand in advanced therapies. The company also generates income from small molecules and capsules/health ingredients, as outlined in its segment structure per Morningstar data as of May 11, 2026. These areas benefit from sticky customer relationships and expertise in high-quality production.

Lonza Group AG's exposure to the US market is significant through OTC listings (LZAGF, LZAGY) and partnerships with American biopharma firms, making it relevant for US investors tracking CDMO growth.

Industry trends and competitive position

The biopharma CDMO market is expanding due to outsourcing trends and complex therapy demands, with Lonza Group AG holding a strong position alongside peers like WuXi Apptec and Catalent. Its focus on cell and gene technologies aligns with industry shifts toward personalized medicine, per sector commentary as of May 2026.

Why Lonza Group AG matters for US investors

Lonza Group AG offers US investors access to a Swiss-listed CDMO with substantial exposure to the US biopharma ecosystem via OTC trading and major clients. The dividend payout in USD and recent analyst upgrades highlight its appeal amid US biotech innovation.

Conclusion

The upcoming ex-dividend date on May 12, 2026, for Lonza Group AG's 5.138 USD payout, combined with Morningstar's buy upgrade on May 11, 2026, underscores the company's shareholder focus and growth potential in biopharma CDMO. With robust segments in biologics and cell therapies, plus US market relevance, it remains a notable name. Investors should monitor Q1 2026 earnings details from the May 8 call for further insights.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.